Table 2.
Ventilatory data, adjunctive therapies, ICU stay and outcomes
| All (n = 139) | TIB (n = 75) | No TIB (n = 64) | p | VEP (n = 108) | No VEP (n = 31) | p | |
|---|---|---|---|---|---|---|---|
| Mechanical ventilation—first 5 days and adjunctive therapies | |||||||
| Lowest PaO2/FiO2 ratio in supine position—(IQR) | 99 (72–132) | 102 (70–133) | 90 (75–129) | 0.546 | 100 (72–133) | 90 (65–115) | 0.360 |
| Lowest PaO2/FiO2 ratio in supine position—no (%) | 0.098* | 0.434* | |||||
| 200–300—no (%) | 6 (4.3%) | 4 (5.3%) | 2 (3.1%) | 5 (4.6%) | 1 (3.2%) | ||
| 100–200—no (%) | 62 (44.6%) | 39 (52.0%) | 23 (35.9%) | 51 (47.2%) | 11 (35.5%) | ||
| < 100—no (%) | 71 (51.1%) | 32 (42.7%) | 39 (60.9%) | 52 (48.1%) | 19 (61.3%) | ||
| Lowest static CRS—mL/cmH2O (IQR) | 40 (32–47) | 39 (30–47) | 40 (35–48) | 0.186 | 40 (32–47) | 40 (30–48) | 0.950 |
| CRS < 40 mL/cmH2O—no (%) | 65 (46.8%) | 38 (50.7%) | 27 (42.2%) | 0.318 | 49 (45.4%) | 16 (51.6%) | 0.539 |
| Neuromuscular blocking agents continuous infusion—no (%) | 124 (89.1%) | 67 (89.3%) | 57 (89.1%) | 0.959 | 97 (89.8%) | 27 (87.1%) | 0.667 |
| Any thromboprophylaxis—no (%) | 139 (100%) | 75 (100%) | 64 (100%) | 1.000 | 108 (100%) | 31 (100%) | 1.000 |
| Enoxaparin therapy—no (%) | 184 (89.2%) | 69 (92%) | 55 (85.9%) | 0.251 | 97 (89.8%) | 27 (87.1%) | 0.667 |
| Enoxaparin daily dose—mg (IQR) | 60 (40–80) | 60 (40–80) | 60 (40–80) | 0.393 | 60 (40–80) | 60 (40–80) | 0.782 |
| Intravenous corticosteroids—no (%) | 96 (69.1%) | 56 (74.7%) | 40 (62.5%) | 0.122 | 77 (71.3%) | 19 (61.3%) | 0.288 |
| Antiplatelet therapy—no (%) | 44 (31.7%) | 24 (32%) | 20 (31.3%) | 0.925 | 33 (30.6%) | 11 (35.5%) | 0.603 |
| ICU stay and outcomes | |||||||
| Tracheotomy—no (%) | 89 (64.0%) | 44 (58.7%) | 45 (70.3%) | 0.154 | 72 (66.7%) | 17 (54.8%) | 0.226 |
| Prone positioning—no (%) | 83 (59.7%) | 43 (57.3%) | 40 (62.5%) | 0.536 | 65 (60.2%) | 18 (58.1%) | 0.832 |
| Cardiovascular complications—no (%) | 35 (25.2%) | 21 (28.0%) | 14 (21.9%) | 0.407 | 28 (25.9%) | 7 (22.6%) | 0.705 |
| Need for RRT—no (%) | 31 (22.3%) | 14 (18.7%) | 17 (26.6%) | 0.265 | 26 (24.1%) | 5 (16.1%) | 0.349 |
| Duration of MV—days (IQR) | 15 (9–24) | 15 (8–23) | 16 (8–24) | 0.297 | 15 (9–24) | 16 (9–23) | 0.652 |
| VFD-28 days—days (IQR) | 0 (0–14) | 0 (0–15) | 0 (0–12) | 0.979 | 0 (0–15) | 0 (0–12) | 0.980 |
| ICU length of stay—days (IQR) | 18 (12–32) | 19 (13–31) | 17 (9–33) | 0.558 | 19 (13–32) | 17 (9–33) | 0.652 |
| ICU mortality—no (%) | 57 (41.0%) | 32 (42.7%) | 25 (39.1%) | 0.667 | 46 (42.6%) | 11 (35.5%) | 0.478 |
CRS respiratory system compliance, IQR interquartile range
Significant p values are reported in bold. *Refers to the p value of the Chi-square test for the whole contingency table for the variable taken into account